Auristone provides epigenomics‑driven molecular profiling for cancer, offering the EPI‑CALL™ test that combines RNA‑Seq and epigenomic analysis to deliver actionable insights such as immune‑cell profiling, tumor microenvironment classification, and gene‑fusion detection for clinicians. For researchers, the Signomax™ platform delivers end‑to‑end RNA‑Seq and ultra‑low‑input Nano‑ChIP‑Seq services with customizable bioinformatics pipelines, leveraging proprietary algorithms trained on Asian epigenomic datasets to accelerate biomarker discovery and precision medicine.
Funding
$4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
1OEVFounders
Product
Problem
Clinicians and researchers lack comprehensive epigenomic data that complement genomic information, limiting the ability to accurately select therapies and discover biomarkers, especially for cancers prevalent in Asian populations.
Solution
Auristone offers epigenomics-driven services to address this gap. For clinicians, the EPI‑CALL™ test integrates bulk RNA‑Seq and whole‑transcriptome sequencing to deliver actionable epigenomic insights alongside existing genomic results, supporting therapy selection such as immunotherapy response prediction, immune‑cell profiling, and detection of gene fusions. For researchers, the Signomax™ platform provides end‑to‑end sample‑to‑report services, including RNA‑Seq and ultra‑low‑input Nano‑ChIP‑Seq, with customizable bioinformatics pipelines that generate publication‑ready data and epigenomic biomarkers. Both offerings leverage next‑generation sequencing and proprietary algorithms trained on Asian epigenomic datasets, enabling more precise molecular profiling for cancer patients and accelerating discovery projects.
Target Audience
Primary customers are oncology clinicians seeking molecular profiling for therapy decision‑making and academic or industry researchers conducting cancer biomarker discovery and epigenomic studies, particularly those focused on Asian patient cohorts.
Features
- EPI‑CALL™ integrates RNA‑Seq/WTS with epigenomic analysis to produce immune profiling, tumor microenvironment classification, and gene‑fusion detection
- Proprietary algorithm predicts immunotherapy response from bulk transcriptomic expression data
- Comparative analysis against curated TCGA and in‑house Asian cancer datasets for immune cell abundance and gene expression benchmarks
- Optional clinical‑grade DNA‑Seq + RNA‑Seq package for combined genomic and epigenomic profiling
- Signomax™ delivers RNA‑Seq and Nano‑ChIP‑Seq services with ultra‑low sample input (1‑2 million cells) and high library‑prep yield
- Customizable bioinformatics pipelines include differential expression, gene‑set enrichment, peak calling, and histone‑modification analysis (H3K4me3, H3K27ac)
- End‑to‑end workflow from sample preparation to data analysis, providing high‑quality, annotated datasets ready for publication
- Turnaround time of 3–4 weeks for clinical reports and rapid delivery for research projects